基于分子亚型的肺大细胞神经内分泌癌的最佳治疗策略
Hakan Yücel1, Tülay Kuş1, Sibel Cangi2
1Department of Medical Oncology, School of Medicine, Gaziantep University, Gaziantep 27410, Turkey.
Journal of clinical medicine
|January 28, 2026
概括
肺大细胞神经内分泌癌 (LCNEC) 的分子亚型可能会指导化疗选择. 接受SCLC类化疗的SCLC亚型LCNEC患者的生存率有所改善,这表明了针对这种罕见癌症的量身定制治疗策略.
科学领域:
- 在瘤学瘤学.
- 肺部医学 肺部医学
- 癌症基因组学 癌症基因组学
背景情况:
- 肺大细胞神经内分泌癌 (LCNEC) 是一种具有不确定的最佳系统治疗的侵袭性胸部恶性瘤.
- 目前转移性LCNEC的治疗策略通常涉及交替的小细胞肺癌 (SCLC) 样和非小细胞肺癌 (NSCLC) 样化疗方案.
- LCNEC的分子亚型正在成为个性化治疗选择的潜在方法.
研究的目的:
- 研究SCLC类与NSCLC类化疗方案在肺大细胞神经内分泌癌 (LCNEC) 的疗效.
- 根据LCNEC分子亚型评估治疗结果,特别是SCLC亚型和NSCLC亚型.
- 确定分子分类是否可以为LCNEC患者提供最佳的全身疗法选择.
主要方法:
- 以现有瘤组织和临床数据对61名在2010年至2024年期间被诊断为LCNEC患者的回顾性分析.
- 根据TP53和RB1的变化,LCNEC病例在分子上被分类为SCLC亚型或NSCLC亚型.
- 化疗方案被分类为SCLC类 (白金+埃托波西德,伊利诺特干或托波特干) 或NSCLC类 (白金+纳或格米西塔). 使用卡普兰-梅尔方法分析了生存结果.
主要成果:
- 总体队列中位数整体存活期 (mOS) 为11.0个月,SCLC类和NSCLC类疗法之间的mOS没有显著差异.
- 在SCLC亚型LCNEC组中,接受SCLC类型化疗的患者与接受NSCLC类型化疗 (6个月) 患者相比,表现出较长的mOS (15个月) 的趋势,尽管在统计学上不显著 (p = 0.47).
- 在NSCLC亚型LCNEC组中,对于任何一种化疗类型都没有观察到显著的生存益处.
结论:
- 肺大细胞神经内分泌癌 (LCNEC) 的分子分类可能是指导系统治疗选择的宝贵工具.
- 类似SCLC的化疗方案可能为SCLC亚型LCNEC的患者提供生存优势.
- 需要进一步的前性研究来验证分子亚型化在优化LCNEC治疗策略中的作用.
相关概念视频
Treatment Strategies for Psychological Disorders
764
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
764
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
595
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
595
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
464
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
495
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
495
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
612
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
612
Adrenergic Receptors: ɑ Subtype
2.9K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.9K


